Core Insights - Abbott Laboratories (ABT) has launched Lingo, its first over-the-counter biowearable continuous glucose monitor (CGM), for Android devices, significantly expanding its user base [2][8] - Lingo targets adults not on insulin, helping them understand how diet, exercise, and stress affect their blood sugar levels, thereby promoting healthier lifestyle choices [3][4] - The introduction of Android support aligns with Abbott's strategy to position CGMs as mainstream wellness tools for diabetes and prediabetes management [3][6] Company Developments - The rollout of Lingo on Android devices enhances its scalability, allowing Abbott to reach a larger audience and remove previous limitations tied to device compatibility [9] - Lingo features user-friendly tools like Lingo Count, which helps users track glucose spikes and improve metabolic health over time [9] - Abbott has reported that users who decrease their Lingo Count can halve the time spent above healthy glucose levels and reduce average glucose by 10% within three months [9] Market Position and Trends - Abbott's market capitalization stands at $218.16 billion, reflecting its strong position in the healthcare sector [7] - The CGM device market is projected to reach $5.74 billion by 2025, with a compound annual growth rate (CAGR) of 7.1% through 2034, driven by the rising prevalence of diabetes and demand for preventive measures [12] - Abbott's strategic focus on metabolic awareness positions it well to capitalize on the growing consumer interest in preventing prediabetes and related health conditions [11]

Key Takeaways Data at ASHP 2025 shows BAX EMR integration reduced safety alerts and improved IV infusion setup.BAX data shows hard limit alerts fell 50.3% and soft limits dropped 30.4% across UTMB hospitals.BAX auto-programming cut median setup time from 10 to 4 seconds and sped alert resolution.Baxter International Inc. (BAX) recently shared real-world data at the American Society of Health-System Pharmacists (“ASHP”) 2025 Midyear Clinical Meeting, highlighting the benefits of integrating smart infusion pu ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Viewpoint - Baxter International Inc. is facing a federal securities class action due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint claims that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm to patients [3]. - As a result of these issues, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [3]. Group 2: Impact on Stock and Legal Proceedings - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, causing the stock to drop by 22.4%, closing at $21.76 on the same day [4]. - Investors are reminded of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit against Baxter [1].

Core Insights - Dividend aristocrat stocks are essential for investors aiming for stability and long-term wealth creation, as they have consistently increased dividends for at least 25 years, showcasing financial discipline and commitment to shareholders [1][2] Dividend Aristocrats Overview - Dividend aristocrats serve as a hedge against economic uncertainty, providing downside protection and consistent payout increases, making them suitable anchors in diversified portfolios [2] - Five highlighted dividend aristocrats for 2026 include Atmos Energy Corporation, Medtronic plc, PepsiCo, Inc., Caterpillar Inc., and S&P Global Inc., all of which exhibit robust dividend growth and steady returns [3][8] Atmos Energy Corporation (ATO) - ATO has raised its annual dividend for 42 consecutive years, with a current quarterly dividend of $1 per share and an annual dividend yield of 2.38% [3][4] - The new dividend for fiscal 2026 is $4 per share, reflecting a nearly 15% increase from fiscal 2025 [4] Medtronic plc (MDT) - MDT has increased its dividend for 48 consecutive years, with a current quarterly dividend of 71 cents and an annual dividend yield of 2.84% [5][6] - The company is expanding its global presence, particularly in the Cardiovascular business, despite facing near-term supply and tariff-related challenges [6] PepsiCo, Inc. (PEP) - PEP has raised its annualized dividend by 5% in 2025, reaching $5.69 per share, marking its 53rd consecutive annual dividend increase [7][9] - The company plans to return $8.6 billion to shareholders in 2025, including $7.6 billion in dividends and $1 billion in buybacks, with an annual dividend yield of 3.78% [9] Caterpillar Inc. (CAT) - CAT has a long history of dividend payments, having raised dividends for 32 consecutive years, with a recent quarterly dividend hike of 7% to $1.51 per share [10][11] - The company returned approximately $1.1 billion to shareholders in dividends and share repurchases in Q3 2025, with an annual dividend yield of 1.01% [11] S&P Global Inc. (SPGI) - SPGI has increased its dividend annually for over 50 years, with a current quarterly dividend of 96 cents and an annualized dividend of $3.84 per share [12][13] - The company reported a strong adjusted operating profit margin of 52.1% and generated free cash flow of $1.4 billion in the last quarter [14]

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit for allegedly making false statements and failing to disclose critical information regarding its competitive position and sales performance in the electrophysiology market [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation and covers purchasers of Integer Holdings common stock from July 25, 2024, to October 22, 2025 [1]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Integer Holdings overstated its competitive position and mischaracterized its electrophysiology devices as growth drivers [3]. Group 2: Financial Performance and Impact - On October 23, 2025, Integer Holdings lowered its full-year 2025 sales guidance, which was below analysts' expectations [4]. - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026 [4]. - Following the announcement, the stock price of Integer Holdings fell by more than 32% [4]. Group 3: Company Background - Integer Holdings operates as a medical device contract development and manufacturing company [2]. - The firm is involved in the electrophysiology market, which is experiencing growth, but the company has faced challenges in maintaining its sales performance [3].

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-890 ...

Industry Overview - The MedTech industry faced significant uncertainties in 2025 due to shifting trade policies, reduced federal funding, and supply-chain disruptions, yet it generated $584 billion in revenues, marking seven consecutive years of growth [1][2] - M&A activity in the industry shifted towards fewer but larger deals, with the average transaction size increasing by 11% from 2024 [2] - Rapid technological advancements, particularly in AI and data science, are reshaping the industry, with over 250 AI-enabled devices authorized by the FDA by September 2025 [3] Key Companies - Intuitive Surgical (ISRG) is expected to achieve 14.3% revenue growth in 2026, driven by the demand for its da Vinci surgical systems and recent FDA clearances [10][11] - Insulet (PODD) reported over $700 million in revenues for Q3 2025, with anticipated revenue and EPS growth of 19.8% and 26.3% respectively in 2026, supported by the expansion of its Omnipod portfolio [12][13] - Boston Scientific (BSX) is projected to see revenue and EPS growth of 11.1% and 13.6% respectively in 2026, bolstered by the success of its WATCHMAN device and FARAPULSE technology [14][15] - IDEXX Laboratories (IDXX) is expected to grow revenues and EPS by 8.9% and 11.6% respectively in 2026, driven by innovations in its Companion Animal Group business [16][17] Medical Advances - Regenerative medicine is emerging as a promising field for treating various injuries and diseases, utilizing stem cells and gene editing technologies [5] - Digital Twins technology is projected to grow at a CAGR of 16.6% from 2025 to 2032, enhancing personalized treatment strategies [6] - AI-powered robotic surgery has shown a 25% reduction in operative time and a 30% decrease in intraoperative complications compared to manual methods [7]

Core Viewpoint - Inspira Technologies has announced a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement (SEPA) to enhance its financial flexibility and support its strategic initiatives [1][4][7]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, generating gross proceeds of approximately $1.8 million [2][9]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - The SEPA allows the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion, without any minimum purchase requirements [4][9]. - The company is not obligated to utilize this facility, providing it with opportunistic capital raising options as needed [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6][9]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing intellectual property portfolio [8][10].

Core Viewpoint - Inspira Technologies has announced a definitive agreement for a registered direct offering of ordinary shares, aiming to raise approximately $1.8 million to support its strategic initiatives and operations [1][2][6]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, resulting in gross proceeds of about $1.8 million [2]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - Inspira has entered into a SEPA with YA, allowing the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion [4]. - There are no minimum purchase requirements under the SEPA, and the company is not obligated to draw on this facility [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with products like the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 [8]. - The company is positioned as an attractive platform within the life-support and MedTech landscape, supported by a growing IP portfolio and multiple cleared products [8].